Moreover, despite the inherent challenges to develop protein–protein disruptors, our structural investigation opens up avenues for therapeutic intervention, as small molecules that may interfere with AR dimerization could be potentially useful for PCa treatment. The gene discussed is AR; the disease is posterior cortical atrophy.